Liquidia targets final YUTREPIA approval May 23, 2025; FY 2024 net loss $130.4M

Liquidia Corp

FY 2024 revenue $14.0M (down from $17.5M) driven by Treprostinil Injection promotion; net loss $130.4M ($1.66/share) vs $78.5M loss prior year.
FDA tentative approval of YUTREPIA (PAH/PH-ILD) granted Aug 2024; final approval expected after NCI exclusivity expires May 23, 2025.
HCRx financing amended for up to $100M: $25M received at closing, $50M contingent on first YUTREPIA sale, $25M upon $100M net sales milestone.
Cash and equivalents $176.5M at Dec 31, 2024, up from $83.7M a year earlier.
ASCENT study (YUTREPIA in PH-ILD) nearing enrollment completion; L606 (liposomal treprostinil) U.S. open-label study ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.